Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Pegasys

Pegasys is a medicine containing the active ingredient(s) peginterferon alfa-2a. On this page you will find out more about Pegasys, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: peginterferon alfa-2a

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Pegasys 180 microgram/0.5 mL injection solution, 4 x 0.5 mL syringes

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Chronic Hepatitis C (CHC): The combination of PEGASYS and COPEGUS is indicated for the treatment of chronic heptitis C in patients who have received no prior interferon therapy (treatment naive patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. The combination of PEGASYS and COPEGUS is also indicated for the treatment of chronic hepatitis C in patients with clinically stable human immunodeficiency virus (HIV) co-infection who have previously not received interferon therapy. PEGASYS monotherapy is indicated for the for the treatment of chronic heptitis C in treatment naive patients (see Dosage and Administration; Chronic Hepatitis C: Treatment naive patients). Patients must be 18 years of age or older and have compensated liver disease. Chronic Hepatitis B (CHB): PEGASYS is indicated for the treatment of chronic heptitis B in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear, colourless to light yellow solution, practically free from particles.
Dosage Form Injection, solution
Route of administration Subcutaneous
Medicine schedule
4 pre-filled syringes with needles: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Syringe
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Protect from Light
Life time 4 Years
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 November 2017

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 3 results

Pegasys Solution for injection -

Pegasys Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Pegasys (peginterferon alfa-2a) information | myVMC

Pegasys (peginterferon alfa-2a) is an interferon medicine used to treat viral infections of the liver such as hepatitis B or C.

Read more on myVMC – Virtual Medical Centre website

Pegasys RBV Combination Therapy Combination pack -

Pegasys RBV Combination Therapy Combination pack - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo